Loading...
A) Martin & Harris Laboratories Ltd incorporated in 1996 at Gurgaon, Haryana is a part of “Apeejay Group”, India’s oldest and largest business conglomerates. Mrs. Sushma Paul Berlia is one of the co-promoter and presidents of Apeejay Stya & Svran Group. Martin & Harris Laboratories Ltd is promoted by her.
B) Martin & Harris Laboratories Ltd is engaged in manufacturing of pharmaceuticals, medicinal chemical & botanical products. Besides the core business, it was undertaken the management of its funds through investment in different avenues fetching good returns i.e mutual funds, equity – quoted & unquoted, etc. Following is the revenue contribution from different business verticals.
Pharma business = 52%
Derivative and Investment business = 48%
C) The company has its units located at Roorkee and UNA Himachal Pradesh. It is constantly taking steps to modernize and expand its manufacturing units to meet international standards.
D) The Company has been awarded “Best Innovative in process & formulation development” by the director-general of health service, ministry of the health & family welfare, Government of India. Has also received “Pharma Excellence Awards 2018” by apex industry chamber ASSOCHAM.
| Price Per Equity Share | ₹ 850 |
| Lot Size | 25 Shares |
| 52 Week High | ₹ 1300 |
| 52 Week Low | ₹ 850 |
| Depository | NSDL Only |
| PAN Number | AABCM0832A |
| ISIN Number | INE03VV01015 |
| CIN | U24239HR1993PLC033630 |
| RTA | RCMC Share Registry Pvt. Ltd. |
| Market Cap (in cr.) | ₹ 340 |
| P/E Ratio | 8.49 |
| P/B Ratio | 0.53 |
| Debt to Equity | 0.01 |
| ROE (%) | 6.33 |
| Book Value | 1606.57 |
| Face Value | 10 |
| Total Shares | 3996040 |
| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 168 | 186 | 205 | 146 |
| Cost of Material Consumed | 64 | 50 | 47 | 41 |
| Gross Margins | 61.9 | 73.12 | 77.07 | 71.92 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Employee Benefit Expenses | 13 | 19 | 25 | 24 |
| Other Expenses | 31 | 47 | 61 | 55 |
| EBITDA | 60 | 70 | 72 | 26 |
| OPM | 35.71 | 37.63 | 35.12 | 17.81 |
| Other Income | 12 | 26 | 24 | 34 |
| Finance Cost | 0 | 0.15 | 0 | 0.6 |
| D&A | 3 | 3 | 4 | 5 |
| EBIT | 57 | 67 | 68 | 21 |
| EBIT Margins | 33.93 | 36.02 | 33.17 | 14.38 |
| PBT | 69 | 93 | 92 | 55 |
| PBT Margins | 41.07 | 50 | 44.88 | 37.67 |
| Tax | 17 | 23 | 24 | 15 |
| PAT | 52 | 70 | 68 | 40 |
| NPM | 30.95 | 37.63 | 33.17 | 27.4 |
| EPS | 133.33 | 175.44 | 170.43 | 100.25 |
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | 35.71 | 37.63 | 35.12 | 17.81 |
| Net Profit Margin | 30.95 | 37.63 | 33.17 | 27.4 |
| Earning Per Share (Diluted) | 133.33 | 175.44 | 170.43 | 100.25 |